Navigation Links
Encap agrees colonic drug delivery licensing deal
Date:9/3/2009

Livingston, United Kingdom, 3rd September 2009 / b3c newswire / - Encap Drug Delivery, the leading provider of development and manufacturing services to the pharmaceutical industry, today announced that it has entered into a licensing agreement with The School of Pharmacy, University of London for the use of their drug delivery system, PHLORALTM. This unique coating technology is designed to target the release of drugs to the colon and will form part of a range of colonic delivery systems promoted by Encap under the name ENCODETM (Encap Colonic Delivery)

Recently colonic drug delivery has gained increased importance, not just for treatment of local diseases associated with the colon, e.g. Crohn's disease, ulcerative colitis, colorectal cancer and IBS, but also for its potential as a site for the absorption of certain molecules due to the decreased levels of efflux transporters and membrane-bound metabolic enzymes known as cytochromes. Its potential suitability for the oral delivery of peptides and proteins, oligonucleotides and vaccines is also an area of increasing interest.

Existing colonic systems generally involve coating the dosage unit with polymeric materials that will not normally dissolve in the low pH of the stomach or upper intestine but will dissolve in the higher pH of the lower intestine. Coatings that rely on a pH dependant system have the potential to be unreliable due to the large intra and inter patient variability in transit times and luminal pH. The new PHLORALTM technology represents a significant improvement in colonic delivery providing fail-safe delivery of drug to the target site by employing two complimentary mechanisms to trigger drug release. As well as a pH dependant coating it also incorporates a component which is broken down specifically by the microbiota in the colonic region.

The power of the new technology has been demonstrated in a recently published scintigraphic study in healthy volunteers (Ibekwe, Khela, Evans and Basit, Alimentary Phamacology & Therapeutics 28(7):911-6, 2008). Dosage units with the combination coating all disintegrated in the colonic area as desired whereas many units coated exclusively with a commercially available pH coating passed through the gastrointestinal tract intact and failed to disintegrate.

One of the drawbacks to colonic delivery is the relatively low amount of water that is available for dissolution of dosage forms in this part of the gastrointestinal tract. The combination of a reliable colonic targeting technology and the delivery of drugs in a liquid dosage form using Encaps liquid fill technologies may provide a significant advance for the delivery of a wide range of drugs to the colon.

Encaps Chief Operating Officer, Dr Stephen Brown said This deal with The School of Pharmacy is an ideal strategic fit for Encap Drug Delivery as we already have a portfolio of drug delivery technologies available for oral dose forms. The ability to use the PHLORALTM technology combined with the flexibility afforded by our liquid fill hard capsule technology, allows us to now offer clients a system with the confidence that colonic delivery will be achieved.

About Encap Drug Delivery - www.encapdrugdelivery.com
Encap was established in 1989 and is a global provider of oral drug delivery and pharmaceutical development services. The company provides clients with fully integrated analytical and formulation development services, clinical trial manufacturing and high volume commercial manufacturing. Encaps state-of-the-art facility in the UK is the worlds largest development and manufacturing facility dedicated to liquid filled hard capsules.

For further information please contact:
Leona Dunlop, Encap Drug Delivery, Units 4, 5 & 6, Oakbank Park Way, Livingston, United Kingdom, EH53 0TH. Tel: +44 (0)1506 448080. E-mail:ldunlop@encapdrugdelivery.com


'/>"/>
b3c newswire

Related biology news :

1. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
2. Jumping genes could make for safer gene delivery system
3. Nanoengineers mine tiny diamonds for drug delivery
4. Computer solution to delivery problem
5. Carnegie Mellon researchers to develop new drug delivery system
6. Researchers develop better membranes for water treatment, drug delivery
7. e-SMART Technologies Continues Delivery of Its New Super SMART Card in South Korea
8. Remarks Prepared for Delivery By Attorney General Michael B. Mukasey At the Ministerial Press Conference
9. Fewer babies born after Caesarean delivery
10. Micro-origami: USC folds up micrometer-scale voxels for drug delivery
11. MIT: Stripes key to nanoparticle drug delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... CO (PRWEB) , ... May 05, 2016 , ... ... diagnostics, is proud to support the National Stroke Association during National Stroke Awareness ... the association’s Facebook and Twitter pages throughout the month. CereScan will donate ...
(Date:5/4/2016)... ... May 04, 2016 , ... Looking for a gift ... premiere hands-on cooking experience. Offering everything from gourmet cooking classes to weekend culinary ... forget. , Guests that visit LaJollaCooks4u share an experience unlike any other. Each ...
(Date:5/4/2016)... ... , ... Proove Biosciences, Inc. , the commercial and research leader in ... . The partnership is designed to advance research in pain genetics in an effort ... With the new agreement, researchers at Proove Biosciences are able to collaborate with Luda ...
(Date:5/4/2016)...  Bayer today announced that a Phase III ... (regorafenib) tablets for the treatment of patients with ... endpoint of a statistically significant improvement in overall ... and safety of regorafenib in patients with HCC ... The safety and tolerability were generally consistent with ...
Breaking Biology Technology: